„Janna and I worked in the same laboratory together at Sanford Burnham Medical Research Institute, where she was a graduate student and I was the lab coordinator for Professor Guy Salvesen. I had the pleasure of working with Janna for 4 years and had the privilege of collaborating with her on several projects. I was particularly impressed by Janna’s ability to handle even the toughest projects. That skill often takes years to develop among graduate students, but it seemed to come perfectly naturally to her. Janna was a fount of information about biochemistry, enzyme kinetics and cell biology. In my absence Janna took on the important role of procuring supplies for our colleagues and I have complete trust in her. Janna’s organizational skills are outstanding and her protocols are extremely well written. So much so that when she was asked to orchestrate the Preuss High School teaching laboratory it went so well she was asked to do it again the following year. Janna had tremendous ideas and was always supportive of our colleagues and coworkers. It is rare that you come across standout talent like Janna. I was always in awe of Janna’s ability to project her scientific research and get people on board with ideas—even people who were initially on completely different pages. Janna’s ability to juggle multiple projects was unlike any I’ve seen before and made a dramatic difference in the productivity of the Salvesen laboratory. Janna is a talented, hard-working and warm co-worker and a joy to collaborate with. As a team member or a leader, Janna earns my highest recommendation. I will miss her!“
Janna Hachmann
COO and Co-Founder at Captain T Cell
Berlin, Berlin, Deutschland
800 Follower:innen
500+ Kontakte
Info
I am a curious and outgoing biochemist with a strong interest in meaningful start-up projects in the biotech area.
I am the COO and co-founder at Captain T Cell, a spin-off project at the MDC in Berlin focused on the development of new therapeutic TCRs for cancer patients.
I hold a Ph.D. in Biomedical Sciences from Sanford Burnham Prebys Medical Discovery Institute in La Jolla, CA. Following my graduate studies, I worked as a scientist at InhibRx, a San Diego-based biotech company focused on the discovery of therapeutic antibodies. After returning to Germany, I worked as a consultant managing health care industry projects funded by the German Federal Ministry of Education and Research (BMBF) before I transferred to the Berlin Institute of Health, where I designed and managed a new funding instrument aiming to support the efficient transfer of basic research to market and assisted in the strategic setup up Berlin Health Innovations, the joint technology transfer office of the BIH and the Charité, designing its services and focus areas.
Aktivitäten
-
Congratulations to our friends at Cellbricks for the establishment of their US subsidiary at The Engine Accelerator. Great to see this bridge being…
Congratulations to our friends at Cellbricks for the establishment of their US subsidiary at The Engine Accelerator. Great to see this bridge being…
Beliebt bei Janna Hachmann
-
🎉 Thrilled to share that Captain T Cell has been nominated as a finalist for the European Lifestars Awards - Celebrating Life Science Leaders in the…
🎉 Thrilled to share that Captain T Cell has been nominated as a finalist for the European Lifestars Awards - Celebrating Life Science Leaders in the…
Beliebt bei Janna Hachmann
-
https://lnkd.in/epq6Xtsm
https://lnkd.in/epq6Xtsm
Beliebt bei Janna Hachmann
Berufserfahrung
Ausbildung
-
Sanford-Burnham Graduate School of Biomedical Sciences
Doctor of Philosophy (Ph.D.) in Biomedical Sciences Biomedical Sciences, General
–
-
The Scripps Research Institute
Master's thesis Biochemistry
–
• Research for the project “Induction of Apoptosis in Tumor Cells through Antibodies from the Immune Repertoire of Cancer Patients“ in the laboratory of Brunhilde H. Felding, Ph.D.
• Biochemical and molecular biology experiments, literature research and data analysis
• Collaboration with internal and external research partners
• Publication of the scientific results in a peer reviewed journal and as a final thesis for the completion of the biochemistry degree…• Research for the project “Induction of Apoptosis in Tumor Cells through Antibodies from the Immune Repertoire of Cancer Patients“ in the laboratory of Brunhilde H. Felding, Ph.D.
• Biochemical and molecular biology experiments, literature research and data analysis
• Collaboration with internal and external research partners
• Publication of the scientific results in a peer reviewed journal and as a final thesis for the completion of the biochemistry degree (Diplomarbeit)
• Acquisition of funding through a fellowship by the German Academic Exchange Service (DAAD)
Veröffentlichungen
-
Forschen für die Tonne? – Die Research-Waste- Problematik
Public Health Forum
The article gives an overview of the research waste problem, which describes research activities that do not aid in the discovery of new findings or knowledge and therefore do not add societal benefit. The responsible parties, main causes and suggested solutions are presented.
(Article in German) -
The Paracaspase MALT1
Biochimie
The human paracaspase MALT1 is a caspase homolog that plays a central role in NF-κB signaling. Over the past few years it has become clear that this is due to a combination of its scaffolding and proteolytic function. Knockout mice and mice expressing a catalytically dead variant of the protease have provided valuable information. This review aims to provide an overview of recent developments regarding the enzymatic mechanism and specificity of MALT1, its substrates discovered to date…
The human paracaspase MALT1 is a caspase homolog that plays a central role in NF-κB signaling. Over the past few years it has become clear that this is due to a combination of its scaffolding and proteolytic function. Knockout mice and mice expressing a catalytically dead variant of the protease have provided valuable information. This review aims to provide an overview of recent developments regarding the enzymatic mechanism and specificity of MALT1, its substrates discovered to date, different mouse models, as well as the role of MALT1 in NF-κB signaling downstream of a variety of different receptors.
Andere Autor:innenVeröffentlichung anzeigen -
Probes to Monitor Activity of the Paracaspase MALT1
Chemistry & Biology
The human paracaspase mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) plays a central role in nuclear factor-kappaB (NF-kappaB) signaling as both a protease and scaffolding protein. Knocking out MALT1 leads to impaired NF-kappaB signaling and failure to mount an effective immune response. However, it is unclear to which degree it is the scaffolding function versus the proteolytic activity of MALT1 that is essential. Previous work involving a MALT1 inhibitor with low…
The human paracaspase mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) plays a central role in nuclear factor-kappaB (NF-kappaB) signaling as both a protease and scaffolding protein. Knocking out MALT1 leads to impaired NF-kappaB signaling and failure to mount an effective immune response. However, it is unclear to which degree it is the scaffolding function versus the proteolytic activity of MALT1 that is essential. Previous work involving a MALT1 inhibitor with low selectivity suggests that the enzymatic function plays an important role in different cell lines. To help elucidate this proteolytic role of MALT1, we have designed activity-based probes that inhibit its proteolytic activity. The probes selectively label active enzyme and can be used to inhibit MALT1 and trace its activity profile, helping to create a better picture of the significance of the proteolytic function of MALT1.
Andere Autor:innenVeröffentlichung anzeigen -
Mechanism and specificity of the human paracaspase MALT1.
Biochemical Journal
The paracaspase domain of MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) is a component of a gene translocation fused to the N-terminal domains of the cellular inhibitor of apoptosis protein 2. The paracaspase itself, commonly known as MALT1, participates in the NF-κB (nuclear factor κB) pathway, probably by driving survival signals downstream of the B-cell antigen receptor through MALT1 proteolytic activity. We have developed methods for the expression and…
The paracaspase domain of MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) is a component of a gene translocation fused to the N-terminal domains of the cellular inhibitor of apoptosis protein 2. The paracaspase itself, commonly known as MALT1, participates in the NF-κB (nuclear factor κB) pathway, probably by driving survival signals downstream of the B-cell antigen receptor through MALT1 proteolytic activity. We have developed methods for the expression and purification of recombinant full-length MALT1 and its constituent catalytic domain alone. Both are activated by dimerization without cleavage, with a similar dimerization barrier to the distantly related cousins, the apical caspases. By using positional-scanning peptidyl substrate libraries we demonstrate that the activity and specificity of full-length MALT1 is recapitulated by the catalytic domain alone, showing a stringent requirement for cleaving after arginine, and with striking peptide length constraints for efficient hydrolysis. Rates of cleavage (kcat/Km values) of optimal peptidyl substrates are in the same order as for a putative target protein CYLD. Thus MALT1 has many similarities to caspase 8, even cleaving the putative target protein CYLD with comparable efficiencies, but with diametrically opposite primary substrate specificity.
Andere Autor:innenVeröffentlichung anzeigen -
Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis
Clin Exp Metastasis
Advanced metastatic disease is difficult to manage and specific therapeutic targets are rare. We showed earlier that metastatic breast cancer cells use the activated conformer of adhesion receptor integrin alphavbeta3 for dissemination. We now investigated if targeting this form of the receptor can impact advanced metastatic disease, and we analyzed the mechanisms involved. Treatment of advanced multi-organ metastasis in SCID mice with patient-derived scFv antibodies specific for activated…
Advanced metastatic disease is difficult to manage and specific therapeutic targets are rare. We showed earlier that metastatic breast cancer cells use the activated conformer of adhesion receptor integrin alphavbeta3 for dissemination. We now investigated if targeting this form of the receptor can impact advanced metastatic disease, and we analyzed the mechanisms involved. Treatment of advanced multi-organ metastasis in SCID mice with patient-derived scFv antibodies specific for activated integrin alphavbeta3 caused stagnation and regression of metastatic growth. The antibodies specifically localized to tumor lesions in vivo and inhibited alphavbeta3 ligand binding at nanomolar levels in vitro. At the cellular level, the scFs associated rapidly with high affinity alphavbeta3 and dissociated extremely slowly. Thus, the scFvs occupy the receptor on metastatic tumor cells for prolonged periods of time, allowing for inhibition of established cell interaction with natural alphavbeta3 ligands. Potential apoptosis inducing effects of the antibodies through interaction with caspase-3 were studied as potential additional mechanism of treatment response. However, in contrast to a previous concept, neither the RGD-containing ligand mimetic scFvs nor RGD peptides bound or activated caspase-3 at the cellular or molecular level. This indicates that the treatment effects seen in the animal model are primarily due to antibody interference with alphavbeta3 ligation. Inhibition of advanced metastatic disease by treatment with cancer patient derived single chain antibodies against the activated conformer of integrin alphavbeta3 identifies this form of the receptor as a suitable target for therapy.
Andere Autor:innenVeröffentlichung anzeigen
Auszeichnungen/Preise
-
Best Presentation Award
Sanford-Burnham Graduate School of Biomedical Sciences Retreat
-
Notable Platform Presentation
Sanford-Burnham Medical Research Institute Cancer Center Retreat
-
Best Presentation Award
Pacific Coast Protease Spring School
-
HHMI Med-into-Grad Scholarship
Howard Hughes Medical Institute / UCSD School of Medicine
• Full-time participation in the Med-into-Grad Initiative – HHMI-sponsored program providing medical education for graduate students
• Participation in all aspects of clinical proceedings in the Hematology-Oncology department at the UCSD Moores Cancer Center as well as Thornton Hospital including tumor boards, case conferences, pathology signout conferences, and continuing medical education
• Inpatient and outpatient clinics with oncology patients and clinical trial participants
-
Student Representative
-
• Representation of the graduate students of the Graduate School of Biomedical Sciences in committee meetings as well as the with the dean and manager of the graduate program from 5/2012 until 5/2014
• Organization of the program retreat including the scientific program -
Fellowship for the Completion of the Final Thesis
German Academic Exchange Service (DAAD)
Sprachen
-
English
Muttersprache oder zweisprachig
-
German
Muttersprache oder zweisprachig
-
Spanish
Gute Kenntnisse
Erhaltene Empfehlungen
2 Personen haben Janna Hachmann empfohlen
Jetzt anmelden und ansehenWeitere Aktivitäten von Janna Hachmann
-
I’m happy to share that I started my new position as Co-Founder & CEO at BrainScape-Medical SA! Let the good times roll and the networks grow. 🎉…
I’m happy to share that I started my new position as Co-Founder & CEO at BrainScape-Medical SA! Let the good times roll and the networks grow. 🎉…
Beliebt bei Janna Hachmann
-
⚠ New Agenda Announcement ⚠ The cell therapy industry is beginning to show great promise with innovation in armouring technologies to improve…
⚠ New Agenda Announcement ⚠ The cell therapy industry is beginning to show great promise with innovation in armouring technologies to improve…
Beliebt bei Janna Hachmann
-
Live update from #NewHaven! BioLabs New Haven officially opened! Justin Elicker Mary Ann Melnick Yale University
Live update from #NewHaven! BioLabs New Haven officially opened! Justin Elicker Mary Ann Melnick Yale University
Beliebt bei Janna Hachmann
-
We are excited to share that we have been honored with the Berlin Economic Award 2024! This award recognizes companies that contribute to Berlin's…
We are excited to share that we have been honored with the Berlin Economic Award 2024! This award recognizes companies that contribute to Berlin's…
Beliebt bei Janna Hachmann
-
After 9+ years, today was my last day at #Bayer! What a ride it has been! Now it time to say Thank You - to my fantastic colleagues, friends, and…
After 9+ years, today was my last day at #Bayer! What a ride it has been! Now it time to say Thank You - to my fantastic colleagues, friends, and…
Beliebt bei Janna Hachmann
-
🌟 Huge thanks to George & Reini! 🌟 20+ years at the CBR and you've made an unforgettable impact. We are beyond excited to see what your next…
🌟 Huge thanks to George & Reini! 🌟 20+ years at the CBR and you've made an unforgettable impact. We are beyond excited to see what your next…
Beliebt bei Janna Hachmann